| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 0 | 3,000 | 0 | 0 |
| Research and development | 427,000 | 362,000 | 469,000 | 185,000 |
| General and administrative | 585,000 | 548,000 | 718,000 | 854,000 |
| Total operating expenses | 1,012,000 | 910,000 | 1,187,000 | 1,039,000 |
| Loss from operations | -1,012,000 | -907,000 | -1,187,000 | -1,039,000 |
| Change in fair value of warrant liability | NaN | 0 | 0 | 31,000 |
| Other income, net | 6,000 | 14,000 | 28,000 | 19,000 |
| Other income (expense), net | NaN | 14,000 | 28,000 | -12,000 |
| Net loss | -1,006,000 | -893,000 | -1,159,000 | -1,051,000 |
| Basic EPS | -0.59 | -0.383 | -0.55 | -0.63 |
| Diluted EPS | -0.59 | -0.383 | -0.55 | -0.63 |
| Basic Average Shares | 1,948,357 | 2,332,792 | 2,183,039 | 1,676,345 |
| Diluted Average Shares | 1,948,357 | 2,332,792 | 2,183,039 | 1,676,345 |
Alaunos Therapeutics, Inc. (TCRT)
Alaunos Therapeutics, Inc. (TCRT)